Skip to main content
. Author manuscript; available in PMC: 2022 Sep 15.
Published in final edited form as: Cancer Res. 2022 Mar 15;82(6):1038–1054. doi: 10.1158/0008-5472.CAN-21-0622

Figure 7: Treatment with ABBV-085 reduces cell viability in LRRC15-expressing human patient-derived ascites.

Figure 7:

(A) Analysis of LRRC15 expression in 7 human patient-derived ascites. β-actin was shown as a loading control. (B) Percent ATP level was analyzed upon treatment with ABBV-085 and drug controls in LRRC15 expressing A4832, (C) A3626, (D) JM067, (E) DC378 and LRRC15 non-expressing (F) A7683 and (G) AM812 ascites cells.